CN109219449B - 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 - Google Patents

包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 Download PDF

Info

Publication number
CN109219449B
CN109219449B CN201780033618.XA CN201780033618A CN109219449B CN 109219449 B CN109219449 B CN 109219449B CN 201780033618 A CN201780033618 A CN 201780033618A CN 109219449 B CN109219449 B CN 109219449B
Authority
CN
China
Prior art keywords
hbsag
antigen
hbcag
virus
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780033618.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109219449A (zh
Inventor
J·C·阿吉拉尔鲁维多
Y·洛拜纳马托
E·伊格莱西亚斯佩雷斯
E·彭顿阿里亚斯
G·E·纪廉涅托
J·A·阿吉亚尔圣地亚哥
S·冈萨雷斯布兰科
J·巴尔德斯埃尔南德斯
M·巴斯克斯卡斯蒂略
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Genetic Engineering and Biotechnology
Original Assignee
Center for Genetic Engineering and Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Genetic Engineering and Biotechnology filed Critical Center for Genetic Engineering and Biotechnology
Publication of CN109219449A publication Critical patent/CN109219449A/zh
Application granted granted Critical
Publication of CN109219449B publication Critical patent/CN109219449B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780033618.XA 2016-03-31 2017-03-14 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物 Active CN109219449B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2016-0038 2016-03-31
PCT/CU2017/050001 WO2017167317A1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (2)

Publication Number Publication Date
CN109219449A CN109219449A (zh) 2019-01-15
CN109219449B true CN109219449B (zh) 2022-08-30

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780033618.XA Active CN109219449B (zh) 2016-03-31 2017-03-14 包含乙型肝炎病毒的表面抗原和核衣壳抗原的药用组合物

Country Status (16)

Country Link
US (2) US11491218B2 (enExample)
EP (1) EP3437654B1 (enExample)
JP (1) JP6981992B2 (enExample)
KR (1) KR20180125985A (enExample)
CN (1) CN109219449B (enExample)
AR (1) AR108009A1 (enExample)
AU (1) AU2017243136B2 (enExample)
CU (1) CU24454B1 (enExample)
EA (1) EA201892212A1 (enExample)
ES (1) ES2965709T3 (enExample)
MX (1) MX2018011793A (enExample)
MY (1) MY202118A (enExample)
TW (1) TWI755383B (enExample)
UA (1) UA128952C2 (enExample)
WO (1) WO2017167317A1 (enExample)
ZA (1) ZA201806325B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4034158A4 (en) * 2019-09-23 2023-10-04 Ascendo Biotechnology, Inc. BIODEGRADABLE NANOCOMPLEX VACCINE, METHODS FOR SUPPRESSING HEPATITIS B VIRUS REPLICATION AND SECRETION OF HEPATITIS B VIRUS SURFACE ANTIGEN
US12577585B2 (en) 2020-01-10 2026-03-17 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles
CU20200028A7 (es) * 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
JP2025506732A (ja) * 2022-02-22 2025-03-13 カロジェン コーポレイション 感染症およびがんの免疫療法適用のための多用途のウイルス様小胞（ｖｌｖ）プラットフォーム
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1477972A (zh) * 2000-12-01 2004-02-25 �Ŵ����������＼������ 获得抗原性聚集物的方法及其在制剂中的用途
CN102665687A (zh) * 2009-09-29 2012-09-12 遗传工程与生物技术中心 用于细胞刺激随后进行治疗性免疫的乙肝病毒抗原制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CN104338132A (zh) * 2013-07-26 2015-02-11 复旦大学 一种病毒免疫治疗药物复合物及其用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1477972A (zh) * 2000-12-01 2004-02-25 �Ŵ����������＼������ 获得抗原性聚集物的方法及其在制剂中的用途
CN102665687A (zh) * 2009-09-29 2012-09-12 遗传工程与生物技术中心 用于细胞刺激随后进行治疗性免疫的乙肝病毒抗原制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A VLP Library of C-Terminally Truncated Hepatitis B Core Proteins: Correlation of RNA Encapsidation with a Th1/Th2 Switch in the Immune Responses of Mice;Irina Sominskaya等;《PLoS One》;20130923;第8卷(第9期);第1页摘要，图1-2,4-5 *
Comparison of the immune response induced in mice by five commercial vaccines based on recombinant HBsAg from different sources, implications on their therapeutic use;Yadira Lobaina等;《Biotecnología Aplicada》;20080101;第25卷(第4期);第325页摘要，第326页右栏第2段，第329页右栏第4-5段，第330页左栏第4段 *
Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens;Arístides AguilarBetancourt等;《International Journal of Infectious Diseases》;20070124;第11卷(第5期);第394-401页 *
Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B;Mamun Al-Mahtab等;《Hepatology International》;20131109;第7卷;第981页摘要，第982页右栏第2段，第983页左栏第3-4段，表1 *

Also Published As

Publication number Publication date
ZA201806325B (en) 2020-08-26
TW201735945A (zh) 2017-10-16
KR20180125985A (ko) 2018-11-26
WO2017167317A1 (es) 2017-10-05
AR108009A1 (es) 2018-07-04
US20200297840A1 (en) 2020-09-24
TWI755383B (zh) 2022-02-21
UA128952C2 (uk) 2024-12-11
CU24454B1 (es) 2019-11-04
US11491218B2 (en) 2022-11-08
EP3437654B1 (en) 2023-09-20
MX2018011793A (es) 2018-12-17
CA3017778A1 (en) 2017-10-05
EA201892212A1 (ru) 2019-03-29
ES2965709T3 (es) 2024-04-16
US20220193228A1 (en) 2022-06-23
BR112018069738A2 (pt) 2019-02-05
CU20160038A7 (es) 2017-11-07
AU2017243136B2 (en) 2022-02-17
MY202118A (en) 2024-04-04
EP3437654A1 (en) 2019-02-06
HK1259329A1 (zh) 2019-11-29
CN109219449A (zh) 2019-01-15
US11759517B2 (en) 2023-09-19
JP2019510064A (ja) 2019-04-11
AU2017243136A1 (en) 2018-10-11
JP6981992B2 (ja) 2021-12-17

Similar Documents

Publication Publication Date Title
US11759517B2 (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis B virus
CN103476426A (zh) 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂
JP2024161488A (ja) Ｂ型肝炎免疫化レジメン及び組成物
JP2021506771A (ja) Ｂ型肝炎免疫化レジメン及び組成物
JP2013505971A (ja) 治療上の免疫化後の細胞性刺激のためのｂ型肝炎ウイルス抗原製剤
CA3017778C (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
HK1259329B (en) Pharmaceutical composition that includes the surface and nucleocapsid antigens of the hepatitis b virus
JP5102209B2 (ja) 切り詰め型ｈｂｃコアタンパク質と、サポニンが主成分の免疫増進剤とを含有するワクチン
EA040981B1 (ru) Фармацевтическая композиция, которая включает поверхностные и нуклеокапсидные антигены вируса гепатита b
RU2362586C2 (ru) Фармацевтические композиции для терапевтического применения
BR112018069738B1 (pt) Composição farmacêutica, e, uso da mesma
US20220288187A1 (en) Biodegradable nanocomplex vaccines, methods for suppression of hepapitis b virus replication and hepapitis b virus surface antigen secretion
CN118019754A (zh) 诱导pres特异性中和抗体的hbv疫苗
WO2025172435A1 (en) Hbv antigen formulation for treating hepatitis b
김채영 Preclinical study on a novel DNA vaccine (HB-110) for the treatment of chronic Hepatitis B virus infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259329

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant